Skip to main content
Premium Trial:

Request an Annual Quote

George Golumbeski, Onaiza Cadoret-Manier, Fred Kohler, Angela Lai

Grail has added to its executive team, hiring George Golumbeski as president, Onaiza Cadoret-Manier as chief commercial officer, and Fred Kohler as vice president of people. The firm has also promoted Angela Lai to chief technology officer.

Golumbeski most recently served as executive vice president of business development for Celgene, and currently serves on the boards of several biotechnology companies, including KSQ Therapeutics, Carrick Therapeutics, Enanta Pharmaceuticals, and MorphoSys. He will replace Ken Drazan as president, who has stepped down to work on helping early-stage start-up firms secure funding. Drazan will continue to serve as an advisor to Grail. Golumbeski will also join Grail's board of directors.

Cadoret-Manier joins Grail from Genentech where she was vice president of the respiratory franchise. Previously, she held various senior management positions overseeing sales and marketing for several products at Genentech, Pfizer, Amylin Pharmaceuticals, and Quest Diagnostics.

Kohler has joined Grail from Roche, where he most recently led transformation work. Kohler previously worked at Autodesk and Juniper Networks, where he held a variety of human resources roles.

Lai has served as vice president of clinical technology at Grail since July 2016. She was responsible for building Grail's software systems team and supporting the company's clinical studies.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.